Circulating Tumour DNA (ctDNA) Blood Test

Early discovery is the best way to treat cancer.

  • Accurate testing
  • Covers 28 common cancers
  • Examines 400,000 genetic loci
The Earlier Cancer Is Found, the Better the Chances of Successful Treatment

Statistics show that 5-year survival rates for common cancers such as breast cancer, ovarian cancer and prostate cancer are as high as 90% with early diagnosis and treatment, while the 5-year survival rate with late-stage diagnosis is around 30%.

Source: SEER Cancer Statistics, National Cancer Institute

Annual Checkups Don’t Necessarily Find Cancer Early

Cancer is one of the leading causes of death, with a case being confirmed roughly every 6 minutes. Most cacners are caused by cellular changes that are hard to detect with conventional examination methods (including imaging and tumour markers), so it is important to track changes in malignant tumour cell DNA to effectively detect cancer at an early stage.

Modern technology allows us to test for traces of cancerous gene mutations in the bloodstream, effectively and accurately discovering precancerous pathological changes and kill cancer before it takes root. Circulating tumour DNA (ctDNA) is one of the most advanced techniques used in cancer prevention today and has the twin advantages of high accuracy and comprehensive detection. The key technologies involved are able to overcome the difficulties of detecting traces of changes in dead tumour cell DNA fragments, allowing us to achieve highly sensitive and integrated detection of cell-free genetic variations within the blood serum or plasma.

Our lab uses deep next generation sequencing (NGS) techniques that require just 10ml of blood and are capable of analysing 400,000 genetic loci covering 28 types of cancer in men and women. This allows you to estimate your risk of cancer at the earliest possible opporunity, helping you to take preventative action in a timely manner and massively increase your chances of successful treatment.

Here is a list of 28 diseases that can be detected at an early stage with ctDNA testing:
  • Nasopharyngeal cancer
  • Gastrointestinal stromal tumours
  • Colorectal cancer
  • Bile duct cancer
  • Non-Hodgkin lymphoma (NHL)
  • Non-small-cell lung carcinoma (NSCLC)
  • Small cell lung cancer
  • Liver cancer
  • Osteosarcoma
  • Melanoma (skin cancer)
  • Throat cancer
  • Hodgkin lymphoma
  • Acute myeloid leukemia (AML)
  • Thyroid cancer
  • Urethral cancer
  • Bladder cancer
  • Soft tissue sarcoma
  • Kidney cancer
  • Adrenal carcinoma
  • Esophageal squamous cell carcinoma (ESCC)
  • Esophageal adenocarcinoma
  • Stomach cancer
  • Pancreatic cancer
  • Mediastinal tumor
Men only:
  • Testicular cancer
  • Myelodysplastic syndromes (MDS)
  • Prostate cancer
  • Head and neck cancers
Women only:
  • Cervical cancer
  • Ovarian cancer
  • Breast cancer
  • Endometrial carcinoma
This test requires only a 20ml sample of venous blood. The results are generally available in 30 business days.